
This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!
Skip to main page content
U.S. flag

An official website of the United States government
Here's how you know
NIH NLM Logo
Log in
Close
Account
Logged in as:
username

    Dashboard
    Publications
    Account settings
    Log out

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
pubmed logo
Search:

 

Search
Advanced Clipboard
User Guide
Save Email
Send to

    Clipboard
    My Bibliography
    Collections
    Citation manager 

Display options
Display options
Format
Full text links
full text provider logo Atypon
Actions
Cite
Collections
Add to Collections
Share

    Permalink
    Copy

Page navigation

    Title & authors
    Abstract
    Comment in
    Similar articles
    Cited by
    Publication types
    MeSH terms
    Related information
    LinkOut - more resources

N Engl J Med
Actions

    Search in PubMed
    Search in NLM Catalog
    Add to Search 

.
IF: 158.5 Q1
2011 Oct 13;365(15):1375-83.
doi: 10.1056/NEJMoa1103042 .
Incidence of adenocarcinoma among patients with Barrett's esophagus
Frederik Hvid-Jensen   1 ,  Lars Pedersen ,  Asbjørn Mohr Drewes ,  Henrik Toft Sørensen ,  Peter Funch-Jensen
Affiliations Expand

    PMID: 21995385
    DOI: 10.1056/NEJMoa1103042

Free article
Item in Clipboard
Abstract

Background: Accurate population-based data are needed on the incidence of esophageal adenocarcinoma and high-grade dysplasia among patients with Barrett's esophagus.

Methods: We conducted a nationwide, population-based, cohort study involving all patients with Barrett's esophagus in Denmark during the period from 1992 through 2009, using data from the Danish Pathology Registry and the Danish Cancer Registry. We determined the incidence rates (numbers of cases per 1000 person-years) of adenocarcinoma and high-grade dysplasia. As a measure of relative risk, standardized incidence ratios were calculated with the use of national cancer rates in Denmark during the study period.

Results: We identified 11,028 patients with Barrett's esophagus and analyzed their data for a median of 5.2 years. Within the first year after the index endoscopy, 131 new cases of adenocarcinoma were diagnosed. During subsequent years, 66 new adenocarcinomas were detected, yielding an incidence rate for adenocarcinoma of 1.2 cases per 1000 person-years (95% confidence interval [CI], 0.9 to 1.5). As compared with the risk in the general population, the relative risk of adenocarcinoma among patients with Barrett's esophagus was 11.3 (95% CI, 8.8 to 14.4). The annual risk of esophageal adenocarcinoma was 0.12% (95% CI, 0.09 to 0.15). Detection of low-grade dysplasia on the index endoscopy was associated with an incidence rate for adenocarcinoma of 5.1 cases per 1000 person-years. In contrast, the incidence rate among patients without dysplasia was 1.0 case per 1000 person-years. Risk estimates for patients with high-grade dysplasia were slightly higher.

Conclusions: Barrett's esophagus is a strong risk factor for esophageal adenocarcinoma, but the absolute annual risk, 0.12%, is much lower than the assumed risk of 0.5%, which is the basis for current surveillance guidelines. Data from the current study call into question the rationale for ongoing surveillance in patients who have Barrett's esophagus without dysplasia. (Funded by the Clinical Institute, University of Aarhus, Aarhus, Denmark.).
    Q1
    IF:  158.5
    Cited by:  Load 497 
    Sci-Hub Link 
    PDF(Full Text) 
    Citation
    Collect

PubMed Disclaimer
Comment in

    The problems with surveillance of Barrett's esophagus.
    Kahrilas PJ. Kahrilas PJ. N Engl J Med. 2011 Oct 13;365(15):1437-8. doi: 10.1056/NEJMe1108435 . N Engl J Med. 2011. PMID: 21995392 No abstract available.
    Barrett esophagus: Need for ongoing surveillance called into question for patients with non-dysplastic Barrett esophagus.
    Wood NJ. Wood NJ. Nat Rev Gastroenterol Hepatol. 2011 Dec 5;8(12):657. doi: 10.1038/nrgastro.2011.204 . Nat Rev Gastroenterol Hepatol. 2011. PMID: 22138905 No abstract available.
    Adenocarcinoma in Barrett's esophagus.
    Barret M, Chaussade S, Coriat R. Barret M, et al. N Engl J Med. 2011 Dec 29;365(26):2539; author reply 2539-40. doi: 10.1056/NEJMc1113052 . N Engl J Med. 2011. PMID: 22204731 No abstract available.
    [Risk of adenocarcinoma in patients with Barrett esophagus is significantly less than previously assumed].
    Steurer J. Steurer J. Praxis (Bern 1994). 2012 Jan 4;101(1):59-60. doi: 10.1024/1661-8157/a000811 . Praxis (Bern 1994). 2012. PMID: 22219077 German. No abstract available.
    Reflux and Barrett's disease. Can we stop surveillance after 2011?
    Bisschops R. Bisschops R. Endoscopy. 2012 Apr;44(4):362-5. doi: 10.1055/s-0031-1291741 . Epub 2012 Feb 27. Endoscopy. 2012. PMID: 22370699 No abstract available.
    Where is the truth when it comes to cancer risk in Barrett's esophagus?
    di Pietro M, O'Donovan M, Fitzgerald RC. di Pietro M, et al. Gastroenterology. 2012 May;142(5):1245-7. doi: 10.1053/j.gastro.2012.03.017 . Epub 2012 Mar 20. Gastroenterology. 2012. PMID: 22445710 No abstract available.

Similar articles

    Dysplasia and risk of further neoplastic progression in a regional Veterans Administration Barrett's cohort.
    Dulai GS, Shekelle PG, Jensen DM, Spiegel BM, Chen J, Oh D, Kahn KL. Dulai GS, et al. Am J Gastroenterol. 2005 Apr;100(4):775-83. doi: 10.1111/j.1572-0241.2005.41300.x . Am J Gastroenterol. 2005. PMID: 15784018
    Adenocarcinoma of the esophagus and Barrett's esophagus: a population-based study.
    Bytzer P, Christensen PB, Damkier P, Vinding K, Seersholm N. Bytzer P, et al. Am J Gastroenterol. 1999 Jan;94(1):86-91. doi: 10.1111/j.1572-0241.1999.00776.x . Am J Gastroenterol. 1999. PMID: 9934736
    The incidence of adenocarcinoma and dysplasia in Barrett's esophagus: report on the Cleveland Clinic Barrett's Esophagus Registry.
    O'Connor JB, Falk GW, Richter JE. O'Connor JB, et al. Am J Gastroenterol. 1999 Aug;94(8):2037-42. doi: 10.1111/j.1572-0241.1999.01275.x . Am J Gastroenterol. 1999. PMID: 10445525
    Treatment of Barrett's esophagus with high-grade dysplasia.
    McAllaster JD, Buckles D, Al-Kasspooles M. McAllaster JD, et al. Expert Rev Anticancer Ther. 2009 Mar;9(3):303-16. doi: 10.1586/14737140.9.3.303 . Expert Rev Anticancer Ther. 2009. PMID: 19275509 Review.
    Barrett's esophagus and risk of esophageal adenocarcinoma.
    Cossentino MJ, Wong RK. Cossentino MJ, et al. Semin Gastrointest Dis. 2003 Jul;14(3):128-35. Semin Gastrointest Dis. 2003. PMID: 14653412 Review.

See all similar articles
Cited by

    Endoscopic Follow-Up Between 3 and 7 Years After Sleeve Gastrectomy Reveals Antral Reactive Gastropathy but no Barrett's Esophagus.
    Coupaye M, Gorbatchef C, Dior M, Pacheco A, Duboc H, Calabrese D, Moszkowicz D, Le Gall M, Chen R, Soliman H, Ledoux S. Coupaye M, et al. Obes Surg. 2023 Oct;33(10):3112-3119. doi: 10.1007/s11695-023-06785-y . Epub 2023 Aug 22. Obes Surg. 2023. PMID: 37605066
    The Local Microbiome in Esophageal Cancer and Treatment Response: A Review of Emerging Data and Future Directions.
    Pandey A, Lieu CH, Kim SS. Pandey A, et al. Cancers (Basel). 2023 Jul 10;15(14):3562. doi: 10.3390/cancers15143562 . Cancers (Basel). 2023. PMID: 37509225 Free PMC article. Review.
    Germline Determinants of Esophageal Adenocarcinoma.
    Lee M, Eng G, Handte-Reinecker A; MGH-MIT Gastrointestinal Cohorts Working Group; Deshpande VS, Yilmaz OH, Gala MK. Lee M, et al. Gastroenterology. 2023 Nov;165(5):1276-1279.e7. doi: 10.1053/j.gastro.2023.07.015 . Epub 2023 Jul 26. Gastroenterology. 2023. PMID: 37507074 Free PMC article. No abstract available.
    Real-world implementation of non-endoscopic triage testing for Barrett's oesophagus during COVID-19.
    Landy R, Killcoyne S, Tang C, Juniat S, O'Donovan M, Goel N, Gehrung M, Fitzgerald RC. Landy R, et al. QJM. 2023 Sep 12;116(8):659-666. doi: 10.1093/qjmed/hcad093 . QJM. 2023. PMID: 37220898 Free PMC article.
    What Is "Cold" and What Is "Hot" in Mucosal Ablation for Barrett's Oesophagus-Related Dysplasia: A Practical Guide.
    Spadaccini M, Alfarone L, Chandrasekar VT, Maselli R, Capogreco A, Franchellucci G, Massimi D, Fugazza A, Colombo M, Carrara S, Facciorusso A, Bhandari P, Sharma P, Hassan C, Repici A. Spadaccini M, et al. Life (Basel). 2023 Apr 15;13(4):1023. doi: 10.3390/life13041023 . Life (Basel). 2023. PMID: 37109552 Free PMC article. Review.

See all "Cited by" articles
Publication types

    Research Support, Non-U.S. Gov't
    Actions
        Search in PubMed
        Search in MeSH
        Add to Search 

MeSH terms

    Adenocarcinoma / epidemiology*
    Actions
        Search in PubMed
        Search in MeSH
        Add to Search 
    Adenocarcinoma / etiology
    Actions
        Search in PubMed
        Search in MeSH
        Add to Search 
    Adult
    Actions
        Search in PubMed
        Search in MeSH
        Add to Search 
    Aged
    Actions
        Search in PubMed
        Search in MeSH
        Add to Search 
    Barrett Esophagus / complications*
    Actions
        Search in PubMed
        Search in MeSH
        Add to Search 
    Cohort Studies
    Actions
        Search in PubMed
        Search in MeSH
        Add to Search 
    Denmark / epidemiology
    Actions
        Search in PubMed
        Search in MeSH
        Add to Search 
    Esophageal Neoplasms / epidemiology*
    Actions
        Search in PubMed
        Search in MeSH
        Add to Search 
    Esophageal Neoplasms / etiology
    Actions
        Search in PubMed
        Search in MeSH
        Add to Search 
    Esophagus / pathology*
    Actions
        Search in PubMed
        Search in MeSH
        Add to Search 
    Female
    Actions
        Search in PubMed
        Search in MeSH
        Add to Search 
    Humans
    Actions
        Search in PubMed
        Search in MeSH
        Add to Search 
    Incidence
    Actions
        Search in PubMed
        Search in MeSH
        Add to Search 
    Male
    Actions
        Search in PubMed
        Search in MeSH
        Add to Search 
    Middle Aged
    Actions
        Search in PubMed
        Search in MeSH
        Add to Search 
    Precancerous Conditions / epidemiology*
    Actions
        Search in PubMed
        Search in MeSH
        Add to Search 
    Precancerous Conditions / etiology
    Actions
        Search in PubMed
        Search in MeSH
        Add to Search 
    Proportional Hazards Models
    Actions
        Search in PubMed
        Search in MeSH
        Add to Search 
    Risk Factors
    Actions
        Search in PubMed
        Search in MeSH
        Add to Search 

Related information

    Cited in Books
    MedGen 

LinkOut - more resources

    Full Text Sources
        Atypon
        Ovid Technologies, Inc. 
    Other Literature Sources
        H1 Connect
        The Lens - Patent Citations 
    Medical
        Genetic Alliance
        MedlinePlus Health Information 
    Research Materials
        NCI CPTC Antibody Characterization Program 
    Miscellaneous
        NCI CPTAC Assay Portal 

Full text links [x]
full text provider logo Atypon
[x]
Cite
Copy
Download .nbib .nbib
Format:
Send To

    Clipboard
    Email
    Save
    My Bibliography
    Collections
    Citation Manager

[x]

NCBI Literature Resources

MeSH PMC Bookshelf Disclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.
Follow NCBI
Twitter Facebook LinkedIn .cls-11,.cls-12{fill:#737373}.cls-11{fill-rule:evenodd} GitHub .cls-1{fill:#737373}

Connect with NLM

    .st20{fill:#FFFFFF}.st30{fill:none;stroke:#FFFFFF;stroke-width:8;stroke-miterlimit:10} SM-Twitter
    .st10{fill:#FFFFFF}.st110{fill:none;stroke:#FFFFFF;stroke-width:8;stroke-miterlimit:10} SM-Facebook
    SM-Youtube .st4{fill:none;stroke:#FFFFFF;stroke-width:8;stroke-miterlimit:10}.st5{fill:#FFFFFF}

National Library of Medicine
8600 Rockville Pike
Bethesda, MD 20894

Web Policies
FOIA
HHS Vulnerability Disclosure

Help
Accessibility
Careers

    NLM
    NIH
    HHS
    USA.gov

CREATE NEW PROJECT
Project Name
Create
Abandon
